Imatinib mesylate (IM) or Glivec (NOVARTIS Pharma) is a selective molecular inhibitor of the BCR-ABL oncogene protein and permits long term disease control in about two thirds of chronic phase CML patients [2]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.